Published in PLoS One on November 23, 2015
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem (2003) 6.77
n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr (2006) 6.60
Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol (2001) 5.87
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science (2013) 3.64
Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med (2008) 3.35
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol (2008) 2.68
Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med (1997) 2.61
Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med (2009) 2.43
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med (1994) 2.38
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res (2003) 2.12
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood (1981) 2.05
Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med (2000) 2.01
The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 1.96
Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol (2002) 1.95
Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity (2014) 1.85
Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest (1998) 1.83
Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem (1997) 1.66
Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol (2011) 1.63
New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.48
Resolution of acute inflammation in the lung. Annu Rev Physiol (2013) 1.42
Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids (2005) 1.39
Lipoxins: resolutionary road. Br J Pharmacol (2009) 1.35
Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol (2001) 1.17
Tumour necrosis factor-alpha and leukotriene B(4) mediate the neutrophil migration in immune inflammation. Br J Pharmacol (2001) 1.12
Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J Immunol (2013) 1.09
High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis (2013) 1.08
Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol (2006) 1.06
Prostaglandin E-mediated mitogenic stimulation of mouse epidermis in vivo by divalent cation ionophore A 23187 and by tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Cancer Res (1981) 1.05
Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol (2002) 1.02
An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol (2002) 1.01
Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J (2002) 0.98
Natural resolution of inflammation. Periodontol 2000 (2013) 0.97
Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids (2005) 0.95
Eicosanoids in skin inflammation. Prostaglandins Leukot Essent Fatty Acids (2012) 0.95
Identification, cloning, and functional characterization of a murine lipoxin A4 receptor homologue gene. J Immunol (2002) 0.92
What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4? Scand J Immunol (2011) 0.89
Synthesis of lipid mediators during UVB-induced inflammatory hyperalgesia in rats and mice. PLoS One (2013) 0.88
Role of prostanoids in the inflammatory reaction and their therapeutic potential in the skin. Arch Dermatol Res (1992) 0.83
Synthesis and anti-inflammatory and pro-resolving activities of 22-OH-PD1, a monohydroxylated metabolite of protectin D1. J Nat Prod (2014) 0.82
Increase in covalent binding of 5-hydroxydiclofenac to hepatic tissues in rats co-treated with lipopolysaccharide and diclofenac: involvement in the onset of diclofenac-induced idiosyncratic hepatotoxicity. J Toxicol Sci (2012) 0.80
Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors. Scand J Immunol (2009) 0.80
Carrier-mediated transport of lipoxin A4 in human neutrophils. Am J Physiol (1994) 0.80
Membrane morphology is actively transformed by covalent binding of the protein Atg8 to PE-lipids. PLoS One (2014) 0.79
Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄. Biochem Pharmacol (2013) 0.79
Resolution of PMA-induced skin inflammation involves interaction of IFN-γ and ALOX15. Mediators Inflamm (2013) 0.79
Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity. Inflammation (2012) 0.77
Chiral chromatography-tandem mass spectrometry applied to the determination of pro-resolving lipid mediators. J Chromatogr A (2014) 0.76
Chiral chromatography-tandem mass spectrometry applied to the determination of pro-resolving lipid mediators. J Chromatogr A (2014) 0.76
Lipoxin A₄: problems with its determination using reversed phase chromatography-tandem mass spectrometry and confirmation with chiral chromatography. Talanta (2014) 0.75